Shopping Cart 0
Cart Subtotal
USD 0

Baxalta Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Baxalta Inc (Baxalta) is a biopharmaceutical company that develops, manufactures and commercializes therapies for orphan diseases. The company offers products for the treatment of orphan diseases related to cancer, and hematological and immunological diseases. It offers treatment for hemophilia, bleeding disorders, alpha-1 antitrypsin deficiency, immune deficiencies, burns and shock, other chronic and acute medical conditions, and treatment for acute lymphoblastic leukemia. Baxalta's pipeline includes biologics with innovative mechanisms, and advanced technology platforms such as gene therapy and biosimilars. The company sells its products in North America, South America, Europe and Asia-Pacific. The company conducts research through Baxalta Global Innovation and R&D Center in Cambridge, Massachusetts. Baxalta is headquartered in Bannockburn, Illinois, the US.

Baxalta Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Baxalta Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Baxalta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Baxalta Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Baxalta Acquires Oncaspar Portfolio from Sigma-Tau Finanziaria for USD900 Million 12

Venture Financing 13

OncoResponse Raises Additional USD3 Million in Series A Financing 13

Suppremol Raises US$20.6 Million In Series D Financing 14

AesRx Raises US$1.35 Million In Venture Financing 15

Chatham Therapeutics Secures US$0.2 Million In Venture Financing 16

AesRx Secures An Additional US$0.12 Million In Venture Financing 17

Partnerships 17

TR-Pharm Enters into Distribution Agreement with Sigma-Tau Rare Disease 17

Baxalta Enters into Agreement with Precision Biosciences 18

Baxalta Enters into Agreement with Symphogen 19

Novimmune Enters into Research Agreement with Baxalta 19

Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 20

Baxter Enters Into Co-Development Agreement With Chatham Therapeutics For Factor IX Hemophilia B Gene Therapy Treatment 21

Licensing Agreements 22

SuppreMol Exercises Option For Licensing Agreement With Bayerische For RA Antibody 22

Equity Offering 23

Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 23

Baxalta Invests in OncoResponse 24

Debt Offering 25

Baxalta Raises USD375 Million in Private Placement of 2% Notes Due 2018 25

Baxalta Raises USD1 Billion in Private Placement of 2.875% Notes Due 2020 26

Baxalta Raises USD500 Million in Private Placement of 3.6% Notes Due 2022 27

Baxalta Raises USD1.75 Billion in Private Placement of 4% Notes Due 2025 28

Baxalta Raises USD1 Billion in Private Placement of 5.25% Notes Due 2045 29

Baxalta Raises USD375 Million in Private Placement of Floating Rate Notes Due 2018 30

Asset Transactions 31

Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 31

Acquisition 32

Shire Acquires Baxalta for USD32 Billion 32

Baxter International Acquires SuppreMol for USD225 Million 34

Baxter Acquires AesRx 35

Baxter International To Acquire Chatham Therapeutics From Asklepios BioPharma For US$70 Million 36

Baxalta Inc-Key Competitors 38

Key Employees 39

Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 43

Financial Announcements 43

Apr 28, 2016: Baxalta Exceeds Guidance and Delivers Strong Sales and Earnings for First Quarter 2016 43

Feb 16, 2016: Baxalta Posts Strong Fourth Quarter 2015 Sales and Earnings; Positive Momentum Continues with Achievement of Key Milestones 45

Government and Public Interest 47

Jun 27, 2016: BIRD-Israel-U.S. Binational Industrial R&D Foundation to Invest $7.5 Million in 9 New Projects 47

Other Significant Developments 48

Apr 21, 2016: Baxalta Supports Research to Raise Awareness of Treatment Burden on Patients during the Sixth Annual World Primary Immunodeficiency Week 48

Appendix 49

Methodology 49

About GlobalData 49

Contact Us 49

Disclaimer 49


List Of Figure

List of Figures

Baxalta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Baxalta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9


List Of Table

List of Tables

Baxalta Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Baxalta Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Baxalta Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Baxalta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Baxalta Acquires Oncaspar Portfolio from Sigma-Tau Finanziaria for USD900 Million 12

OncoResponse Raises Additional USD3 Million in Series A Financing 13

Suppremol Raises US$20.6 Million In Series D Financing 14

AesRx Raises US$1.35 Million In Venture Financing 15

Chatham Therapeutics Secures US$0.2 Million In Venture Financing 16

AesRx Secures An Additional US$0.12 Million In Venture Financing 17

TR-Pharm Enters into Distribution Agreement with Sigma-Tau Rare Disease 17

Baxalta Enters into Agreement with Precision Biosciences 18

Baxalta Enters into Agreement with Symphogen 19

Novimmune Enters into Research Agreement with Baxalta 19

Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 20

Baxter Enters Into Co-Development Agreement With Chatham Therapeutics For Factor IX Hemophilia B Gene Therapy Treatment 21

SuppreMol Exercises Option For Licensing Agreement With Bayerische For RA Antibody 22

Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 23

Baxalta Invests in OncoResponse 24

Baxalta Raises USD375 Million in Private Placement of 2% Notes Due 2018 25

Baxalta Raises USD1 Billion in Private Placement of 2.875% Notes Due 2020 26

Baxalta Raises USD500 Million in Private Placement of 3.6% Notes Due 2022 27

Baxalta Raises USD1.75 Billion in Private Placement of 4% Notes Due 2025 28

Baxalta Raises USD1 Billion in Private Placement of 5.25% Notes Due 2045 29

Baxalta Raises USD375 Million in Private Placement of Floating Rate Notes Due 2018 30

Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 31

Shire Acquires Baxalta for USD32 Billion 32

Baxter International Acquires SuppreMol for USD225 Million 34

Baxter Acquires AesRx 35

Baxter International To Acquire Chatham Therapeutics From Asklepios BioPharma For US$70 Million 36

Baxalta Inc, Key Competitors 38

Baxalta Inc, Key Employees 39

Baxalta Inc, Subsidiaries 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com